A Randomized, Double-blind, Placebo-Controlled, Repeat-dose, Single-center Phase 1a Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Subjects
Latest Information Update: 09 Mar 2022
At a glance
- Drugs Lanadelumab (Primary)
- Indications COVID 2019 infections; Hereditary angioedema
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 08 Jan 2021 Status changed from active, no longer recruiting to completed.
- 07 Oct 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 11 Aug 2020 New trial record